Portfolio

Portfolio

SCROLL

Juniper Biologics Pte Ltd

Juniper Biologics at a glance

Juniper Biologics is an in-licensing pharmaceutical platform, whose aim is to become a world-class life sciences company, driven by ESG values, to enable access to innovative medications for areas where there exists a need for helping in advancing human lives. Juniper will do this by in-licensing additional patented pharmaceutical products in the areas of oncology, oncology support care, rare diseases, and gene & cell therapy, with a target of US$1 billion of sales by 2032.

Impact Story

Juniper delivers strong impact by improving the quality of life for cancer patients through increasing access to essential medicines at greater affordability. New innovations in the pharmaceutical sector seldom accompany the mission to reduce financial barriers for patients. Market expansion of Akynzeo means more customers will be exposed to a better drug solution with lower expenditure for CINV treatment. The introduction of Anamoreline will also benefit its impact target with great significance, reducing the heavy psychological and physical burden of cancer cachexia patients.

Investment Theme
Inclusive Society
Geography
Singapore
Business
Pharmaceuticals
Investment Year
2021
Fund
Sylvan Asia Growth Fund I
Status
Under Management
SDGs
SDGs 3
Website
https://www.juniperbiologics.com/